Patents by Inventor Joel Z. Melnick

Joel Z. Melnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10220047
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 5, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Publication number: 20180271885
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Publication number: 20180271884
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Publication number: 20180117068
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: September 29, 2017
    Publication date: May 3, 2018
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Publication number: 20180085381
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: August 6, 2015
    Publication date: March 29, 2018
    Applicant: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Publication number: 20180021354
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Patent number: 9861644
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Publication number: 20170067917
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Patent number: 9500661
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: November 22, 2016
    Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Publication number: 20160038514
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: September 25, 2015
    Publication date: February 11, 2016
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Publication number: 20150141385
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Patent number: 8962239
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 24, 2015
    Assignees: Opko Renal, LLC, Opko IP Holdings II, Inc.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Publication number: 20140349979
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 27, 2014
    Applicant: OPKO IP HOLDINGS II, INC.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Publication number: 20130137663
    Abstract: Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.
    Type: Application
    Filed: March 29, 2011
    Publication date: May 30, 2013
    Inventors: Eric J. Messner, P. Martin Petkovich, Jay A. White, Samir P. Tabash, Joel Z. Melnick, Charles W. Bishop
  • Publication number: 20110052567
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Application
    Filed: April 2, 2009
    Publication date: March 3, 2011
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick